Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Fisher

Showing results (151-160 of 251) with videos related to

Pageof 26
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2006
Analysis of protein solvent interactions in glucose dehydrogenase from the extreme halophile Haloferax mediterraneiK Linda Britton, Patrick J Baker, Martin Fisher, et al.
HIV Clinical Trials|August 26, 2010
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trialsMark Nelson, Martin Fisher, Juan Gonzalez-Garcia, et al.
AIDS (London, England)|December 20, 2007
Survival following HIV infection of a cohort followed up from seroconversion in the UKFiona M Ewings, Krishnan Bhaskaran, Ken McLean, et al.
Plos One|November 19, 2013
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infectionSara Lodi, Martin Fisher, Andrew Phillips, et al.
AIDS (London, England)|March 22, 2008
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individualsBrian Angus, Fiona Lampe, Guiseppe Tambussi, et al.
Antiviral Therapy|October 2, 2003
Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patientsCaroline A Sabin, Ed Wilkins, Maurice Murphy, et al.
Plos One|July 31, 2015
The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UKJamie Inshaw, Clifford Leen, Martin Fisher, et al.
Antiviral Therapy|September 28, 2012
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppressionAmanda Mocroft, Wendy P Bannister, Ole Kirk, et al.
BMJ (Clinical Research Ed.)|March 20, 2025
Climate activism: a necessity to protect public healthHilary Neve, Lynne Jones, Katharine Fallon, et al.
Plos One|October 3, 2013
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureSara Lodi, Andrew Phillips, Sarah Fidler, et al.
Pageof 26

Showing results (151-160 of 251) with videos related to

Sort By:
Pageof 26
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2006
Analysis of protein solvent interactions in glucose dehydrogenase from the extreme halophile Haloferax mediterraneiK Linda Britton, Patrick J Baker, Martin Fisher, et al.
HIV Clinical Trials|August 26, 2010
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trialsMark Nelson, Martin Fisher, Juan Gonzalez-Garcia, et al.
AIDS (London, England)|December 20, 2007
Survival following HIV infection of a cohort followed up from seroconversion in the UKFiona M Ewings, Krishnan Bhaskaran, Ken McLean, et al.
Plos One|November 19, 2013
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infectionSara Lodi, Martin Fisher, Andrew Phillips, et al.
AIDS (London, England)|March 22, 2008
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individualsBrian Angus, Fiona Lampe, Guiseppe Tambussi, et al.
Antiviral Therapy|October 2, 2003
Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patientsCaroline A Sabin, Ed Wilkins, Maurice Murphy, et al.
Plos One|July 31, 2015
The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UKJamie Inshaw, Clifford Leen, Martin Fisher, et al.
Antiviral Therapy|September 28, 2012
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppressionAmanda Mocroft, Wendy P Bannister, Ole Kirk, et al.
BMJ (Clinical Research Ed.)|March 20, 2025
Climate activism: a necessity to protect public healthHilary Neve, Lynne Jones, Katharine Fallon, et al.
Plos One|October 3, 2013
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failureSara Lodi, Andrew Phillips, Sarah Fidler, et al.
Pageof 26